May 15 |
Alto Neuroscience reports Q1 GAAP EPS of -$0.76
|
May 14 |
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
May 9 |
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
|
Apr 23 |
Alto Neuroscience schizophrenia treatment shows good phase 1 results
|
Apr 23 |
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
|
Apr 9 |
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions
|
Apr 3 |
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
|
Mar 21 |
Alto Neuroscience GAAP EPS of -$9.73
|
Mar 21 |
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
|
Mar 21 |
Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders
|